|
Cell line
|
2-DG (mM)
|
Platinum (μM)
|
2-DG + Platinum
|
2-DG + 20uM SB202190 (mM)
|
Platinum + 20uM SB202190 (uM)
|
2-DG + 20 μM SB202190 + Platinum
|
|---|
|
2-DG (mM)
|
Platinum (μM)
|
CI at IC50
|
2-DG (mM)
|
Platinum (μM)
|
|---|
|
MIA PaCa-2
|
1.45
|
3.37
|
0.95
|
0.48
|
0.796
|
0.48
|
19.72
|
0.24
|
0.12
|
|
BxPC-3
|
10.80
|
28.13
|
8.12
|
4.06
|
0.896
|
0.60
|
32.50
|
1.23
|
0.61
|
|
ASPC-1
|
11.47
|
>50
|
10.55
|
5.25
|
0.954
|
4.90
|
>50
|
5.77
|
2.88
|
|
OVCAR-3
|
3.39
|
6.93
|
3.39
|
1.69
|
1.243
|
3.9
|
26.45
|
4.1
|
2.05
|
|
HEY
|
10.17
|
32.90
|
9.88
|
4.94
|
1.122
|
2.63
|
50>
|
2.44
|
1.22
|
|
SK-OV-3
|
13.34
|
11.53
|
6.46
|
3.23
|
0.764
|
1.42
|
21.05
|
2.01
|
1.01
|
- IC50 values represent the level of drug that inhibited cell growth by 50% following 48 hours of treatment. Combination index (CI) values are defined as: <0.1 = very strong synergy, 0.1-0.3 = strong synergism, 0.3-0.7 = synergism, 0.7 – 0.85 = moderate synergism, 0.85-0.9 = slight synergism, 0.9-1.1 = nearly additive, 1.1-1.45 slight to moderate antagonism.
